- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
European Society of Cardiology Congress
Billed as the largest cardiology conference of the year, coverage of the European Society of Cardiology Congress will consist of articles, Q&As, exclusive video interviews, and podcasts with leading experts in their respective fields.
Medtronic's External ICD Meets Safety, Efficacy Endpoints in Pivotal Trial
September 01, 2022
In a pivotal trial presented at ESC Congress 2022, Medtronic's investigational external ICD achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global pivotal trial.
An Overview of HFpEF Characteristics, Treatment Patterns, & Outcomes, with Stephen Greene, MD
August 30, 2022
Stephen Greene, MD, discusses a study he presented at ESC Congress 2022 describing the patient characteristics, treatment patterns, and outcomes among people with HFpEF in the US and based on ejection fraction range at baseline.
Statin Muscle Symptom Risk Overblown, Does Not Outweigh CV Benefits, CTT Study Shows
August 29, 2022
Results of a CTT meta-analysis from ESC Congress 22 detail the excess risk of muscle symptoms observed with statin therapy from more than 20 clinical trials assessing statins against placebo or less intensive statin therapy.
PANTHER: P2Y12 Monotherapy Bests Aspirin for Secondary Prevention in Coronary Artery Disease
August 29, 2022
The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.
Milvexian Shows Promise for Preventing Stroke in Phase 2 Dose-Finding Trial
August 28, 2022
A phase 2 dose-finding trial presented at ESC Congress 22 suggests the use of milvexian could reduce the risk of ischemic stroke by up to 30% without a major increase in the risk of bleeding events in certain doses.
Dapagliflozin Proves HFpEF Benefit in DELIVER Trial
August 27, 2022
Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.
DANCAVAS: Universal CVD Screenings Do Not Reduce Risk of Death in Men
August 27, 2022
Results of a trial assessing the impact of universal subclinical CVD screenings found increased screenings did not significantly reduce the risk of all-cause mortality in men aged 65-74 years over the next 5 years.
TIME Study: No Added Benefit from Nighttime Dosing of Blood Pressure Medications
August 26, 2022
Although the Hygia study suggested nighttime dosing could increase the benefit of risk reduction obtained from antihypertensive medications, the TIME study found no significant improvement in risk reduction afforded by nighttime dosing as compared to morning dosing of medication.
Modeling Study Sheds Light on Benefits on Lifelong Statin Therapy
August 25, 2022
A modeling study presented at ESC 2022 provides insight into the differences in potential benefits of statin therapy based on lifelong use, delayed initiation, and early discontinuation among patients across the spectrum of cardiovascular risk.
Using Medical Marijuana for Chronic Pain Could Compromise Cardiovascular Health
August 22, 2022
An analysis of Danish national register data suggests patients using medical cannabis for pain had a 64% greater risk of arrhythmias than their unexposed counterparts.